Immuno-Oncology T Cell Assays
Charles River’s translatable immuno-oncology platform enables oncology researchers to rapidly assess the T-cell-modulated immune function of therapeutic modalities in high-throughput and high-content imaging platforms illustrating T cell activation, increased T cell proliferation, T cell exhaustion, T cell chemotaxis, and cytokine response. Observe T-cell-mediated cytotoxicity in both 2D and 3D platforms. Start your biologic or small molecule on the road to discovery with our optimized T cell assays. Select T cell assays are available in an off-the-shelf format yielding results 3-5 weeks from receipt of compounds.
Available T Cell Assays
- Off-the-Shelf T Cell Assays
-
Custom T Cell Assays: T Cell Checkpoint Sensitive Assays
- SEB-driven stimulation assay (PBMC and DC/CD4 T cell variants)
- T cell proliferation assay (flow-based)
- Tumor killing assays (TKA)
- Tumor cell line TKA
- PDX cell line TKA
- Antigen recall assay (peptide-driven)
- DC/CD4 MLR
- PD mouse model with antigen-specific OT-I and OT-II murine T cells
-
Custom T Cell Assays: T Cell Assays for a Wide Range of Targets
- Polyclonally driven CD8+ Tex assay
- IL-2 stimulation assay (pSTAT5, human, mouse, and NHP)
- Tumor cell line TKA
- PDX cell line TKA
- On/off target testing for TCR cellular therapeutics
- Treg proliferation assay
- Treg suppression assay
- iTreg differentiation assay
- Th1/Th2/Th17 differentiation assay
- TAA-specific T cell responses
- Immune synapse formation
These simple and multicellular T cell assays are validated with standard of care molecules, including checkpoint inhibitors and a selection of small-molecule inhibitors of targets known to modulate immune responses, confirming Charles River’s predictive immuno-oncology platform. This comprehensive panel of T cell assays addresses every step of the cancer-immunity cycle.
 |
Download Cancer-Immunity Cycle Poster
A Translational Platform for Immunotherapeutics
T cell assays are used to generate information on compounds from each stage of the drug discovery process to inform and progress therapies rapidly from in vitro assays to in vivo studies and, ultimately, successfully to the clinic.
Frequently Asked Questions (FAQ) for T Cell Assays
-
What T cell assay should I used to observe the release of cancer cell antigens?
Cytokine response, immunogenic cell death, immunosuppressive signaling markers, expression of check point marker and tumor associated macrophage (TAM) are T-cell assays developed to observe the release of cancer cell antigens.
-
What T cell assay should I used to observe priming and activation?
T cell proliferation, T cell exhaustion, Antigen-specific human CTL/Super-antigen T cell activation, Modelling immune cell synapse formation and maintenance, nTreg, iTreg and T cell differentiation are T-cell assays developed to observe priming and activation.
-
What T cell assay should I used to observe trafficking into tumors?
T cell chemotaxis, T cell/DC adhesion and Trans-endothelial migration are T cell assays developed to observe trafficking into tumors.
-
What T-cell assay should I used to observe the killing of cancer cells?
2D T cell-mediated cytotoxicity, 3D spheroid T cell-mediated cytotoxicity, NK cell cytotoxicity and ADCC are T cell assays developed to observe the killing of cancer cells
Interview with our Lead Oncology Scientist: Developing a Translational Immuno-Oncology Platform